Closing the Design–Make–Test–Analyze Loop: Interplay between Experiments and Predictions Drives PROTACs Bioavailability
Journal of Medicinal Chemistry · 28.11.2024 · 67 (22) · 20242-20257
DOI: 10.1021/acs.jmedchem.4c01642 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 08.11.2024. Verfasst von Zulma Santisteban Valencia und 13 weiteren Autor:innen. Beteiligte Einrichtung: Assays, Profiling and Cell Sciences, Discovery Sciences, R&D, AstraZeneca, Mölndal SE-431 83, Sweden. Hauptthemen laut MEDLINE: Biological Availability, Proteolysis, Drug Design. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 69 Literaturangaben. Gefördert von: AstraZeneca M?lndal.
Abstract (Originalsprache)
The drug development landscape is expanding to include drug modalities such as PROteolysis-TArgeting Chimeras (PROTACs) and peptides, offering possibilities for previously intractable biological targets. However, with their size and chemical nature, they diverge from established frameworks for the prediction of oral bioavailability. This evolution to larger and more complex molecules necessitates new methodologies and prediction models to continuously expand on bioavailability guidelines. We describe the high-capacity adoption of two chromatographic physicochemical assays and their application for iterative compound optimization to achieve oral bioavailability. We further describe how these data underpin the continuous refinement of internal machine learning models, which guide compound synthesis decisions in the molecular design phase. Based on data for a set of 691 PROTACs, and two project examples, we confirm a sweet spot for oral bioavailability at log D values higher than the norm for small molecules and show how experimental data and prediction models synergize to effectively drive chemistry optimization.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Assays, Profiling and Cell Sciences, Discovery Sciences, R&D, AstraZeneca, Mölndal SE-431 83, Sweden.
- Oncology Chemistry, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K.
- Medicinal Chemistry, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Mölndal SE-431 83, Sweden.
- Compound Synthesis and Management, Discovery Sciences, R&D, AstraZeneca, Mölndal SE-431 83, Sweden.
- Medicinal Chemistry, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Mölndal SE-431 83, Sweden.
- Physical and Analytical Chemistry, Medicinal Chemistry, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Mölndal SE-431 83, Sweden.
ORCID-Profile: Filip Miljković, Silvio Di Castro, Erik Malmerberg, Stig D Friis, Thomas Lundbäck, Johan Wernevik
Förderung
- AstraZeneca M?lndal
Zitieren
APA
Santisteban Valencia, Z., Kingston, J., Miljković, F., Rowbottom, H., Mann, N., Davies, S., Ekblad, M., Di Castro, S., Kwapień, K., Malmerberg, E., Friis, S. D., Lundbäck, T., Leek, T., & Wernevik, J. (2024). Closing the Design–Make–Test–Analyze Loop: Interplay between Experiments and Predictions Drives PROTACs Bioavailability. Journal of Medicinal Chemistry, 67(22), 20242-20257. https://doi.org/10.1021/acs.jmedchem.4c01642
Vancouver
Santisteban Valencia Z, Kingston J, Miljković F, Rowbottom H, Mann N, Davies S, et al. Closing the Design–Make–Test–Analyze Loop: Interplay between Experiments and Predictions Drives PROTACs Bioavailability. Journal of Medicinal Chemistry. 2024;67(22):20242-20257. doi:10.1021/acs.jmedchem.4c01642
BibTeX
@article{SantistebanValencia2024,
author = {Santisteban Valencia, Zulma and Kingston, Jennifer and Miljković, Filip and Rowbottom, Hannah and Mann, Nadia and Davies, Sophie and Ekblad, Martin and Di Castro, Silvio and Kwapień, Karolina and Malmerberg, Erik and Friis, Stig D and Lundbäck, Thomas and Leek, Tomas and Wernevik, Johan},
title = {Closing the Design–Make–Test–Analyze Loop: Interplay between Experiments and Predictions Drives PROTACs Bioavailability},
journal = {Journal of Medicinal Chemistry},
year = {2024},
volume = {67},
number = {22},
pages = {20242--20257},
doi = {10.1021/acs.jmedchem.4c01642}
}
EUVIMED